Farglitazar
Farglitazar had been in phase ⅡI clinical trials by GlaxoSmithKline for the treatment of type 2 diabetes. However, it was discontinued in 2003.
Farglitazar had been in phase Ⅱ clinical trials for the treatment of hepatic fibrosis. However, no recent development has been reported.
General Information
Update Date：2016-03-30
- Drug Name：
- Farglitazar
- Research Code：
- GI-262570
- Trade Name：
- MOA：
- Peroxisome proliferator-activated receptor-γ agonist
- Indication：
- Type 2 diabetes
- Status：
- Phase Ⅲ (Discontinued)
- Company：
- GlaxoSmithKline (Originator)
- Sales：
- ATC Code：
Chemical Structure
Update Date：2015-10-19
|
Molecular Weight | 546.61 | ||||||||||||
| Formula | C34H30N2O5 | |||||||||||||
| CAS No. | 196808-45-4 (Farglitazar); | |||||||||||||
| Chemical Name | L-Tyrosine, N-(2-benzoylphenyl)-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- | |||||||||||||
| Farglitazar （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||